BCL2 and B-cell chronic lymphocytic leukemia: Currently the antisense oligonucleotide with bcl-2 as the target gene (trade name: Oblimersen) is in Phase III clinical trials with the permit of FDA (mainly treat malignant melanoma, chronic lymphocytic leukemia, multiple myeloma, etc.)[19].